Stock listing

Frankfurt:8ZD Abbisko Cayman Limited Aktie

German listing (Frankfurt) of Abbisko Cayman Limited · home listing HKEX:2256

Follow Abbisko Cayman Limited into a list and get an email when it puts out news.

Share price · FWB:8ZD

€0.695 EUR -0.010 (-1.4%)

Close on Nov 20, 2026

Past year -53.8% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.645 – €0.695 EURNov 20, 2026
Market cap
€497.7M EURAt the close on Nov 20, 2026 · price × 716.2M shares outstanding
52-week range
€0.645 – €1.621 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€1,151 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Abbisko Cayman Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2256 · Home$5.68 HKD-0.62 (-9.8%)2,641,000$6.065$6.065$5.64$6.30Close on Nov 20, 2026
Frankfurt:8ZD€0.695 EUR-0.010 (-1.4%)—€0.655€0.695€0.645€0.705Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:8ZD · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.706-0.073-9.4%€0.711€0.719€0.7050
€0.779+0.040+5.4%€0.779€0.784€0.7770
€0.739+0.059+8.7%€0.743€0.744€0.7390
€0.680-0.050-6.8%€0.689€0.696€0.67027,200
€0.730+0.031+4.4%€0.715€0.740€0.7040
€0.699-0.020-2.8%€0.699€0.699€0.69944,000
€0.719-0.024-3.2%€0.718€0.721€0.7150
€0.743+0.003+0.4%€0.743€0.743€0.74322,000
€0.740-0.036-4.6%€0.740€0.740€0.7340
€0.776+0.007+0.9%€0.776€0.776€0.7760
€0.769-0.021-2.7%€0.778€0.784€0.7660
€0.790-0.053-6.3%€0.792€0.803€0.7820
€0.843-0.005-0.6%€0.839€0.857€0.8350
€0.848-0.013-1.5%€0.850€0.860€0.8450
€0.861-0.005-0.6%€0.857€0.864€0.8510
€0.866+0.047+5.7%€0.861€0.874€0.8600
€0.819-0.022-2.6%€0.819€0.820€0.8190
€0.841-0.019-2.2%€0.841€0.841€0.8410
€0.860-0.001-0.1%€0.865€0.876€0.8600
€0.861-0.024-2.7%€0.868€0.870€0.8600
€0.885-0.019-2.1%€0.890€0.890€0.8810
€0.904-0.055-5.7%€0.911€0.911€0.9030
€0.959-0.045-4.5%€0.968€0.972€0.9590
€1.004+0.017+1.7%€1.004€1.004€1.0040
€0.987+0.007+0.7%€0.981€0.988€0.9810
€0.980-0.024-2.4%€0.976€0.987€0.9740
€1.004+0.011+1.1%€1.009€1.009€0.9990
€0.993+0.023+2.4%€0.989€0.999€0.9810
€0.970+0.002+0.2%€0.974€0.986€0.9670
€0.968-0.017-1.7%€0.968€0.968€0.9680
€0.985-0.007-0.7%€0.987€1.000€0.9850
€0.992-0.036-3.5%€0.992€0.992€0.9920
€1.028+0.024+2.4%€1.028€1.028€1.0280
€1.004+0.018+1.8%€1.021€1.026€1.0040
€0.986+0.057+6.1%€0.984€0.988€0.9800
€0.929+0.023+2.5%€0.929€0.936€0.9280
€0.906+0.003+0.3%€0.912€0.914€0.9050
€0.903-0.038-4.0%€0.903€0.903€0.9030
€0.941+0.008+0.9%€0.929€0.947€0.9230
€0.933+0.011+1.2%€0.938€0.942€0.9310
€0.922+0.010+1.1%€0.927€0.935€0.9170
€0.912-0.040-4.2%€0.912€0.912€0.9120
€0.952-0.003-0.3%€0.956€0.958€0.9500
€0.955-0.013-1.3%€0.962€0.962€0.9530
€0.968+0.009+0.9%€0.972€0.972€0.9510
€0.959-0.016-1.6%€0.967€0.968€0.9590
€0.975+0.002+0.2%€0.977€0.982€0.9750
€0.973+0.031+3.3%€0.974€0.974€0.9710
€0.942-0.062-6.2%€0.969€0.977€0.9420
€1.004+0.002+0.2%€0.968€1.004€0.9670
€1.002-0.067-6.3%€1.002€1.003€1.0020
€1.069+0.001+0.1%€1.071€1.072€1.0690
€1.068-0.002-0.2%€1.070€1.070€1.0650
€1.070-0.001-0.1%€1.059€1.073€1.0550
€1.071-0.041-3.7%€1.068€1.075€1.0640
€1.112-0.030-2.6%€1.112€1.112€1.1120
€1.142+0.028+2.5%€1.142€1.142€1.1420
Ticker
Frankfurt:8ZD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Abbisko Cayman Limited news

Abbisko Cayman Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 38 in all · newest Nov 19, 2026 · oldest 2021
Decks
7 decks · latest Aug 13, 2024

Where Abbisko Cayman Limited is listed

ListingExchangeCountryCurrency
HKEX:2256 和譽 · Home listingHKEXHong KongHKD
LS Exchange:A3C4Y0LS ExchangeGermanyEUR
Lang & Schwarz:A3C4Y0Lang & SchwarzGermanyEUR
Frankfurt:8ZD · This pageFrankfurtGermanyEUR
Dusseldorf:8ZDDusseldorfGermanyEUR
Stuttgart:8ZDStuttgartGermanyEUR

Valuation

Price/book 1.6× against a median of 2.2×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$1.79B HKD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.0Mn/an/an/a1.6×n/a0.2×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
ArriVent BioPharma, Inc. · NASDAQ:AVBPUS$544.1MUS$151.2Mn/a30.2×n/a1.4×n/a0.0×1.18
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Alumis Inc. · NASDAQ:ALMSUS$512.6MUS$116.5Mn/a16.1×n/a1.4×n/a0.1×1.58
Electra Therapeutics, Inc. · NASDAQ:ETRAUS$509.8MUS$107.3Mn/an/an/a1.3×n/a0.0×n/a
Wave Life Sciences Ltd. · NASDAQ:WVEUS$504.9MUS$74.16Mn/a1.1×n/a1.3×−296.9%0.0×1.70
Adlai Nortye Group Ltd. · NASDAQ:ANLUS$502.2MUS$297.0Mn/a59.4×n/a2.3×−710.6%0.1×1.96
Steminent Biotherapeutics, Inc. · TPEX:7729US$496.9MUS$470.4Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.1Mn/a23.2×n/a2.2×−200.8%0.0×n/a
Median of the othersUS$511.2MUS$316.2M30.2×2.2×−296.9%0.0×1.58

Forecasts

Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
19.35 HKD · Analysts' mean
EPS, year to Dec 2026
-0.54 · 6 analysts
Revenue, year to Dec 2026
284.4M · 5 analysts

Team and board

OfficerRole
Yao-Chang XuFounder & CEO
Jia FENGVP, HR and Operations
Zhen ZHANGCMC VP
Hongping YuCo-founder, CSO
Jing JIChief Medical Officer

Events

QuarterResultsShare move
Q2 2025Sep 15, 2025−6.1%
Q1 2025Jun 18, 2025 · Before open+2.9%
Q4 2022Mar 14, 2023 · After close+6.7%
Q2 2022Sep 27, 2022 · After close−2.7%

Open Events

Decks

Open Decks

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue596.3M504.0M19.1M022.7M03.84M
Cost of revenue000000
Gross profit596.3M504.0M19.1M022.7M03.84M
Research and development495.3M451.4M433.7M378.7M226.1M132.7M81.5M
Selling, general and administrative75.8M74.2M35.6M29.8M54.8M9.11M12.1M
Operating income27.2M-21.6M-511.1M-497.2M-328.2M-153.8M-134.1M
Depreciation and amortization22.3M23.6M18.4M15.8M11.9M9.49M8.19M
EBITDA49.5M1.98M-492.7M-481.4M-316.3M-144.3M-125.9M
Interest expense3.25M1.61M2.17M2.69M959.0K338.0K523.0K
Income before tax113.4M78.0M-431.6M-495.6M-1.81B-706.6M-133.9M
Income tax59.6M49.7M2.69M-4.94M172.0K-221.0K
Net income53.8M28.3M-431.6M-498.3M-1.81B-706.8M-133.7M
Earnings per share, basic0.080.04-0.67-0.80-7.68-1.01-0.19

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents749.3M289.5M578.1M2.26B2.55B617.8M285.6M
Short-term investments1.35B1.67B918.0K93.8M26.5M18.9M11.4M
Receivables15.0M47.7M17.8M9.12M39.0K
Current assets2.13B2.02B2.04B2.41B2.58B649.8M300.2M
Property, plant and equipment69.3M77.3M69.3M14.8M20.1M
Total assets2.35B2.11B2.12B2.49B2.65B666.0M320.2M
Current liabilities427.3M135.4M109.2M107.6M73.5M31.7M17.8M
Long-term debt01.72B758.0M
Total debt303.6M24.3M35.7M45.6M53.8M4.31M8.90M
Total liabilities430.4M148.7M134.3M143.2M118.5M1.77B779.3M
Shareholders' equity1.92B1.96B1.98B2.35B2.54B-1.10B-459.0M
Shares outstanding639.8M649.6M647.2M620.7M234.9M702.5M702.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations79.3M-12.9M-444.7M-343.9M-169.7M-117.6M-82.8M
Capital spending-5.53M-7.40M-12.3M-22.7M-12.3M-4.03M-3.44M
Free cash flow73.8M-20.3M-457.0M-366.6M-182.1M-121.6M-86.3M
Cash from investing211.9M-196.5M378.5M-216.6M-1.46B-11.2M30.1M
Cash from financing186.9M-80.9M-16.1M-20.8M2.10B505.9M176.9M
Share buybacks-96.2M-76.3M-12.9M-4.05M1.45B511.0M182.6M
Change in cash459.5M-288.6M-63.8M-422.0M446.1M332.1M131.8M

Open Financials

Filings

FilingDateTypeFiled with
VOLUNTARY ANNOUNCEMENT - Abbisko Therapeutics Presents Preclinical Findings on Novel Selective CDK4 Inhibitor ABSK192 in Single-Agent and Combination Studies at 2026 ENANov 18, 2026Operations updateHKEX
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE BOARD OF THE COMPANYNov 11, 2026Ownership change noticeHKEX
INSIDE INFORMATION - PIMJETMI (pimicotinib) Receive U.S. FDA Approval for TGCTNov 10, 2026Operations updateHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 2, 2026Monthly returnHKEX
CHANGE OF COMPANY NAMENov 1, 2026Other filingsHKEX
Next Day Disclosure ReturnsOct 30, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 29, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 27, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 23, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 21, 2026Next day disclosure returnHKEX
All 25 filings
FilingDateTypeFiled with
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIA GRANTED ORPHAN DESIGNATION BY EMAOct 21, 2026Other filingsHKEX
Next Day Disclosure ReturnsOct 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 15, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 14, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 8, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 7, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 6, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 5, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 2, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 2, 2026Monthly returnHKEX
Next Day Disclosure ReturnsSep 29, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsSep 28, 2026Next day disclosure returnHKEX
2026 INTERIM REPORTSep 22, 2026Interim reportHKEX
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIASep 20, 2026ResultsHKEX
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 17, 2026Sep 17, 2026Meeting outcomeHKEX

Open Filings

Cap table

Built by 6ix from Abbisko Cayman Limited’s releases

Common shares
716,157,350
Fully diluted
716,157,350

Fully diluted

LineShares
Common shares716,157,350

Share count over time

CountShares
Nov 22, 2026716,157,350

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
Yu Hongping165M23.4%Oct 13, 2021
Xu Yao-Chang81.6M11.2%Sep 29, 2026
Trident Trust Company (HK) Limited80.2M11.1%Apr 28, 2026
HERY International Development Limited70.3M9.7%Apr 28, 2026
Yaochang Family Holding Limited70.3M9.7%Apr 28, 2026
Morgan Stanley52.5M7.5%Nov 5, 2021
GIC Private Limited51M7.0%Jul 30, 2026
Allianz SE50.9M7.0%Sep 2, 2026
Elbrus Investments Pte. Ltd.46.5M6.6%Oct 13, 2021
Fullerton Management Pte Ltd46.5M6.6%Oct 13, 2021
All 21 holders
HolderSharesOf the companyAs of
Temasek Life Sciences Private Limited46.5M6.6%Oct 13, 2021
Qiming GP VI, L.P.40.8M6.0%Oct 2, 2025
Qiming Venture Partners VI, L.P.40.8M6.0%Oct 2, 2025
Qiming Corporate GP VI, Ltd.41.1M5.7%Apr 28, 2026
Shi Yi40.9M5.7%Apr 28, 2026
LAV Asset Management (Hong Kong) Limited40.9M5.7%Apr 28, 2026
Futu Trustee Limited40.9M5.7%Apr 28, 2026
Morgan Stanley Investments (UK)39M5.5%Oct 13, 2021
Morgan Stanley & Co. International plc39M5.5%Oct 13, 2021
Morgan Stanley International Limited39M5.5%Oct 13, 2021
Morgan Stanley International Holdings Inc.39M5.5%Oct 13, 2021

Funds

HolderSharesValueAs of
Fidelity China Region Fund11.8MUS$15.2MJul 31, 2026
Vanguard Total International Stock Index Fund7.28MUS$9.35MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund7.23MUS$9.27MJul 31, 2026
iShares Core MSCI Emerging Markets ETF6.21MUS$7.72MMay 31, 2026
Fidelity Series Emerging Markets Opportunities Fund2.47MUS$3.17MJul 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund1.99MUS$2.55MJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF561KUS$769KJun 30, 2026
Vanguard Total World Stock Index Fund479KUS$615KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account341KUS$469KJun 30, 2026
Fidelity Total International Index Fund314KUS$404KJul 31, 2026
All 21 holders
HolderSharesValueAs of
WisdomTree China ex-State-Owned Enterprises Fund312KUS$428KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF243KUS$333KJun 30, 2026
iShares MSCI China Small-Cap ETF215KUS$268KMay 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF108KUS$134KMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio100KUS$137KJun 30, 2026
Vanguard ESG International Stock ETF100KUS$124KMay 31, 2026
iShares Core MSCI Total International Stock ETF73,000US$93,667Jul 31, 2026
Avantis Emerging Markets Small Cap Equity ETF55,000US$68,430May 31, 2026
State Street(R) SPDR(R) S&P(R) China ETF53,000US$72,653Jun 30, 2026
State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF8,000US$10,967Jun 30, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund7,000US$9,007Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Hongping YuCo-founder, CSO · Since at least Nov 5, 2026
Jia FENGVP, HR and Operations · Since at least Nov 5, 2026
Jing JIChief Medical Officer · Since at least Nov 5, 2026
Yao-Chang XuFounder & CEO · Since at least Jun 10, 2025
Zhen ZHANGCMC VP · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Abbisko Cayman Limited.